ClinicalTrials.gg
Not yet recruitingNCT07108023EHPVO-HEMUpdated Aug 6, 2025

Hematological Disorders in EHPVO Patients

An observational study in Extrahepatic Portal Vein Obstruction (EHPVO), Thrombophilia and Myeloproliferative Neoplasms (MPN), sponsored by Rahab Nady. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by Rahab Nady · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
115
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study focuses on patients who have a condition called extrahepatic portal vein obstruction (EHPVO), where a blood clot blocks the portal vein outside the liver. This blockage can cause problems like an enlarged spleen, bleeding from swollen veins in the digestive system, and low blood cell counts. Many of these patients may have hidden blood disorders that increase the risk of clotting, such as myeloproliferative neoplasms (MPNs), antiphospholipid syndrome (APS), or paroxysmal nocturnal hemoglobinuria (PNH). This study will collect and analyze blood test results-such as complete blood count (CBC), liver function tests (LFTs), and clotting tests-from patients with EHPVO. The aim is to find patterns that may suggest an underlying blood disorder, even if the patient doesn't show obvious symptoms.By understanding these patterns early, doctors may be able to diagnose and treat the root causes of clotting in these patients more accurately, helping prevent complications and improve outcomes.

Read the detailed description

Extrahepatic portal vein obstruction (EHPVO) is a non-cirrhotic cause of portal hypertension that results from a thrombotic blockade in the portal vein outside the liver. The preserved hepatic parenchyma distinguishes EHPVO from intrahepatic causes of portal hypertension. However, complications like variceal bleeding, hypersplenism, and splenomegaly remain common. Hematological abnormalities frequently observed in EHPVO include thrombocytopenia, anemia, and leukopenia, often attributed to hypersplenism. Yet, in a subset of patients, especially those with concurrent myeloproliferative neoplasms (MPNs), these cytopenias may be masked due to increased production of blood elements. Coagulation profiles may also show subtle abnormalities or evidence of underlying thrombophilia.A growing body of literature suggests a strong association between EHPVO and underlying prothrombotic conditions such as MPNs (often linked to JAK2V617F mutation), antiphospholipid syndrome (APS), and paroxysmal nocturnal hemoglobinuria (PNH).

Early identification of these disorders may significantly impact clinical management, prognosis, and long-term surveillance. The current study is a cross-sectional observational analysis aiming to investigate the hematological spectrum in patients with EHPVO at Assiut University Hospital. Data will be collected retrospectively from medical records, including CBC with differential, liver function tests, coagulation parameters, and specific thrombophilia workups when available. The primary objective is to correlate these laboratory findings with underlying hematological disorders. Secondary aims include evaluating the association between these abnormalities and clinical outcomes such as variceal bleeding, transfusion needs, and prognosis. The study may offer valuable insights into risk stratification and highlight the importance of thrombophilia screening in this patient population.

02

Conditions studied

  • Extrahepatic Portal Vein Obstruction (EHPVO)
  • Thrombophilia
  • Myeloproliferative Neoplasms (MPN)
  • Antiphospholipid Syndrome (APS)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Thrombocytopenia
  • Anemia
  • Leukopenia

Keywords

  • Portal vein thrombosis
  • EHPVO
  • Hypersplenism
  • Hematological disorders
  • Coagulation profile
  • Liver function tests
  • CBC
  • JAK2 mutation
  • Thrombosis in MPN
  • Cross-sectional study
03

In context

Thrombophilia

88 studies on the registry are indexed under Thrombophilia; 13 are open to participants now.

This study's planned enrollment of 115 is close to the median of 117 across 56 observational studies indexed under Thrombophilia.

Browse Thrombophilia studies →

Lead sponsor

This is the only study on the registry with Rahab Nady as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients diagnosed with EHPVO between 2020 and 2024 in a tertiary care hospital in Cairo. Data will be collected retrospectively from medical records

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older . Diagnosis of extra hepatic portal vein obstruction based on imaging ( Doppler, CT , MRI ) preserved liver function . Available complete medical records including CBC , LFTs and coagulation profile .

Exclusion criteria

Exclusion Criteria:

  • Patients with cirrhosis or intrahepatic portal hypertension • Incomplete or missing medical records • Patients with known hematologic or undergoing chemotherapy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
115 participants (estimated)
Patient registry
No

Groups and cohorts

  • EHPVO Patients

    Patients diagnosed with extrahepatic portal vein obstruction (EHPVO) based on imaging (Doppler ultrasound, CT, or MRI) and with preserved liver function. This group will be assessed for hematological abnormalities, including cytopenias and coagulation disturbances, using retrospective laboratory data.

    Other: No intervention (Observational Study)

Interventions

  • OtherNo intervention (Observational Study)

    This is a retrospective observational study with no assigned intervention. Data will be collected from patient medical records only

06

What researchers measure

Primary outcomes

  1. Frequency of hematological disorders in EHPVO patients

    The proportion of EHPVO Patients showing hematological disorders including cytopenias ( thrombocytopenia , anemia , leukopenia ) and coagulation disturbances based on retrospective laboratory data

    Time frame: Over a retrospective period from 2020 to 2024

  2. Frequency of hematological disorders in EHPVO patients

    Time frame: Over a retrospective period from 2020 to 2024

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

Individual participant data

Plan to share: Yes — De-identified individual participant data, including complete blood count (CBC), liver function tests (LFTs), and coagulation profile results, will be shared. No personally identifiable information will be included.

Supporting information: Study protocol

Time frame: IPD and supporting documents will be available starting 6 months after publication of the primary results and will remain available for up to 5 years after publication.

Access criteria: Access to the de-identified individual participant data (IPD), including CBC, LFTs, and coagulation profiles, will be granted to qualified researchers for academic and non-commercial purposes. Requests should be submitted to the Principal Investigator and will be reviewed on a case-by-case basis. A data use agreement may be required before access is granted.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Dec 2025, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 6, 2025
StartEst.
Aug 2025
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07108023
Lead sponsor
Rahab Nady
Responsible party
Rahab Nady (Assistant Lecturer, Assiut University) — Sponsor-investigator
First posted
Aug 6, 2025
Start date
Aug 2025 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Aug 6, 2025

Study contacts

Rehab N Dr Rehab Nady Ali
Contact
reeehabnady@gmail.com
+201099703970
Mohamed Q Professor of internal medicine
principal investigator · Assiut University
Maha M Dr Maha Mohamed Abdelaziz, Dr at Internal medicine
principal investigator · Assiut University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion